Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Gross Margin % : 71.36% (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Clarus Therapeutics Holdings Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Clarus Therapeutics Holdings's Gross Profit for the three months ended in Jun. 2022 was $2.89 Mil. Clarus Therapeutics Holdings's Revenue for the three months ended in Jun. 2022 was $4.05 Mil. Therefore, Clarus Therapeutics Holdings's Gross Margin % for the quarter that ended in Jun. 2022 was 71.36%.

The historical rank and industry rank for Clarus Therapeutics Holdings's Gross Margin % or its related term are showing as below:

CRXTQ's Gross Margin % is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 46.8
* Ranked among companies with meaningful Gross Margin % only.

Clarus Therapeutics Holdings had a gross margin of 71.36% for the quarter that ended in Jun. 2022 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Clarus Therapeutics Holdings was 0.00% per year.

Clarus Therapeutics Holdings Gross Margin % Historical Data

The historical data trend for Clarus Therapeutics Holdings's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarus Therapeutics Holdings Gross Margin % Chart

Clarus Therapeutics Holdings Annual Data

Trend

Dec20

Dec21

Gross Margin %

-36.40

80.51

Clarus Therapeutics Holdings Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Gross Margin %	Get a 7-Day Free Trial			80.06	88.10	71.74	83.45	71.36

Competitive Comparison of Clarus Therapeutics Holdings's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Clarus Therapeutics Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clarus Therapeutics Holdings's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Clarus Therapeutics Holdings's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Clarus Therapeutics Holdings's Gross Margin % falls into.

Clarus Therapeutics Holdings Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Clarus Therapeutics Holdings's Gross Margin for the fiscal year that ended in Dec. 2021 is calculated as

Gross Margin % (A: Dec. 2021 )	=	Gross Profit (A: Dec. 2021 )	/	Revenue (A: Dec. 2021 )
	=	11.2	/	13.957
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(13.957 - 2.72)	/	13.957
	=	80.51 %

Clarus Therapeutics Holdings's Gross Margin for the quarter that ended in Jun. 2022 is calculated as

Gross Margin % (Q: Jun. 2022 )	=	Gross Profit (Q: Jun. 2022 )	/	Revenue (Q: Jun. 2022 )
	=	2.9	/	4.05
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(4.05 - 1.16)	/	4.05
	=	71.36 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Clarus Therapeutics Holdings (OTCPK:CRXTQ) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Clarus Therapeutics Holdings had a gross margin of 71.36% for the quarter that ended in Jun. 2022 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Clarus Therapeutics Holdings Gross Margin % Related Terms

Thank you for viewing the detailed overview of Clarus Therapeutics Holdings's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clarus Therapeutics Holdings Inc (OTCPK:CRXTQ) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

555 Skokie Boulevard, Suite 340, Northbrook, IL, USA, 60062

Website

https://www.clarustherapeutics.com

Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.

Executives

Thomas Mcnerney & Partners Lp	10 percent owner	45 S. 7TH ST., SUITE 3060, MINNEAPOLIS MN 55402
Kimberly M Murphy	director	101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Elizabeth Cermak	director	1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Prygocki Mark A Sr	director	C/O MEDICS, 8125 N. HAYDEN RD, SCOTTSDALE AZ 85258
John Kenneth Amory	director	C/O CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Robert E. Dudley	director, officer: Chief Executive Officer	555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Joseph Hernandez	director	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Richard D Peterson	officer: Chief Financial Officer	1110 WEST COMMERCIAL BOULEVARD, FORT LAUDERDALE FL 33309
Frank Jaeger	officer: Chief Commercial Officer	CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Steven A. Bourne	officer: Chief Administrative Officer	555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Ffi Fund Ltd	10 percent owner	DMS HOUSE, 20 GENESIS CLOSE, GRAND CAYMAN, GEORGE TOWN E9 KY1-1208
Thomas, Mcnerney & Partners Ii L.p.	10 percent owner	45 SOUTH 7TH STREET, SUITE 3060, Minneapolis MN 55402
Thomas, Mcnerney & Partners Ii, Llc	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Nominee Ii, Llc	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Associates Ii Lp	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402